{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:17:34Z","timestamp":1761293854970},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13104-018-4036-8","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T19:46:14Z","timestamp":1545421574000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study"],"prefix":"10.1186","volume":"11","author":[{"given":"Md Golam","family":"Hasnain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proggananda","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shomik","family":"Maruf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shah Golam","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F. M. Akhtar","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Be-Nazir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariful","family":"Basher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,22]]},"reference":[{"issue":"8","key":"4036_CR1","doi-asserted-by":"publisher","first-page":"e3020","DOI":"10.1371\/journal.pntd.0003020","volume":"8","author":"R Chowdhury","year":"2014","unstructured":"Chowdhury R, Mondal D, Chowdhury V, Faria S, Alvar J, Nabi SG, Boelaert M, Dash AP. How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data. PLOS Negl Trop Dis. 2014;8(8):e3020.","journal-title":"PLOS Negl Trop Dis"},{"key":"4036_CR2","unstructured":"Health ministers commit to eliminating kala-azar [Media advisory]. New Delhi: WHO regional office for South East Asia; 2014 September 9\u201311\n                    http:\/\/www.searo.who.int\/mediacentre\/releases\/2014\/pr1581\/en\/\n                    \n                  . Accessed 30 May 2016."},{"key":"4036_CR3","unstructured":"Kala-azar elimination program [Internet]. Report of a WHO consultation of partners, Geneva, Switzerland; 2015 February 10\u201311\n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/185042\/1\/9789241509497_eng.pdf\n                    \n                  . Accessed 30 May 2016."},{"issue":"1","key":"4036_CR4","first-page":"1","volume":"4","author":"MAJ Chowdhury","year":"1993","unstructured":"Chowdhury MAJ, Alam MN, Hussain A, Rafiquddin AK, Rahman KMA. A study on the treatment of Bangladeshi Kala-azar patients with different dosage regiments of sodium antimony gluconate. Bangl J Med. 1993;4(1):1\u20135.","journal-title":"Bangl J Med"},{"issue":"2","key":"4036_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-3156.2006.01782.x","volume":"12","author":"V Vanlerberghe","year":"2007","unstructured":"Vanlerberghe V, Diap G, Guerin PJ, Meheus F, Gerstl S, Van der Stuyft P, Boelaert M. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Health. 2007;12(2):274\u201383.","journal-title":"Trop Med Int Health."},{"issue":"2","key":"4036_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1517\/14656566.2015.973850","volume":"16","author":"S Sundar","year":"2015","unstructured":"Sundar S, Chakravarty J. An update for pharmacotherapy on leishmaniasis. Exp Opin Pharmacother. 2015;16(2):237\u201352.","journal-title":"Exp Opin Pharmacother"},{"issue":"3","key":"4036_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1086\/380971","volume":"38","author":"S Sundar","year":"2004","unstructured":"Sundar S, Mehta H, Suresh AV, Singh SP, Madhukar R, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis. 2004;38(3):377\u201383.","journal-title":"Clin Infect Dis"},{"key":"4036_CR8","unstructured":"Gilead Sciences and World Health Organization establish New 5-year initiative to prevent deaths from visceral leishmaniasis (News release). Gilead, Geneva, Switzerland; 2011, December 8. \n                    http:\/\/investors.gilead.com\/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1637695\n                    \n                  . Accessed 30 May 2016."},{"issue":"1","key":"4036_CR9","first-page":"1","volume":"1","author":"MM Cheeren","year":"2010","unstructured":"Cheeren MM, Sundar S, Rijal S, Faiz A, Millet P, Oliaro P. A review of clinical trials of treatment for visceral leishmaniasis in the Indian sub-continent (Bangladesh, India and Nepal). Trop IKA Net. 2010;1(1):1\u201331.","journal-title":"Trop IKA Net."},{"key":"4036_CR10","unstructured":"National Kala-azar Elimination Program (NKEP), Bangladesh. National uideline for kala-azar case management, 3rd edn; 2015."},{"key":"4036_CR11","first-page":"170","volume":"97","author":"CP Thakur","year":"1993","unstructured":"Thakur CP, Sinha GP, Sharma V, Pandey AK, Kumar M, Verma BB. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res. 1993;97:170\u20135.","journal-title":"Indian J Med Res"},{"issue":"8937","key":"4036_CR12","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0140-6736(94)90406-5","volume":"344","author":"M Mishra","year":"1994","unstructured":"Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994;344(8937):1599\u2013600.","journal-title":"Lancet"},{"issue":"1","key":"4036_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","volume":"17","author":"CP Thakur","year":"2001","unstructured":"Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents. 2001;17(1):67\u201370.","journal-title":"Int J Antimicrob Agents"},{"key":"4036_CR14","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa021556","volume":"347","author":"S Sundar","year":"2002","unstructured":"Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739\u201346.","journal-title":"N Engl J Med"},{"key":"4036_CR15","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1056\/NEJMoa066536","volume":"356","author":"S Sundar","year":"2007","unstructured":"Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007;356:2571\u201381.","journal-title":"N Engl J Med"},{"issue":"5","key":"4036_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1086\/520665","volume":"45","author":"S Sundar","year":"2007","unstructured":"Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis. 2007;45(5):556\u201361.","journal-title":"Clin Infect Dis"},{"key":"4036_CR17","first-page":"14","volume":"113","author":"CP Thakur","year":"2001","unstructured":"Thakur CP, Ahmed S. Observations on amphotericin B treatment of kala-azar given in a rural set up in Bihar, India. Indian J Med Res. 2001;113:14\u20138.","journal-title":"Indian J Med Res."},{"issue":"1","key":"4036_CR18","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S2214-109X(13)70118-9","volume":"2","author":"D Mondal","year":"2014","unstructured":"Mondal D, Alvar J, Hasnain MG, Hossain MS, Ghosh D, Huda MM, Nabi SG, Sundar S, Matlashewski G, Arana B. Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. Lancet Global Health. 2014;2(1):e51\u20137.","journal-title":"Lancet Global Health"},{"issue":"1","key":"4036_CR19","first-page":"1","volume":"4","author":"MAJ Chowdhury","year":"1993","unstructured":"Chowdhury MAJ, Alam MN, Hussain A, Rafiquddin AK, Rahman KMA. A study on the treatment of Bangladeshi Kala-azar patients with different dosage regiments of sodium antimony gluconate. Bangladesh J Med. 1993;4(1):1\u20135.","journal-title":"Bangladesh J Med"},{"issue":"1","key":"4036_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","volume":"85","author":"M Rahman","year":"2011","unstructured":"Rahman M, Ahmed BN, Faiz MA, Chowdhury MZ, Islam QT, Sayeedur R, Rahman MR, Hossain M, Bangali AM, Ahmad Z, Islam MN, Mascie-Taylor CG, Berman J, Arana B. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg. 2011;85(1):66\u20139.","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"4036_CR21","doi-asserted-by":"publisher","first-page":"e0004118","DOI":"10.1371\/journal.pntd.0004118","volume":"9","author":"KM Jamil","year":"2015","unstructured":"Jamil KM, Haque R, Rahman R, Faiz MA, Bhuiyan AT, Kumar A, Hassan SM, Kelly H, Dhalaria P, Kochhar S, Desjeux P, Bhuiyan MA, Khan MM, Ghosh RS. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis. 2015;9(10):e0004118.","journal-title":"PLoS Negl Trop Dis."}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-018-4036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-018-4036-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-018-4036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T19:20:16Z","timestamp":1576956016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-018-4036-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4036"],"URL":"https:\/\/doi.org\/10.1186\/s13104-018-4036-8","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"29 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"918"}}